Netherlands Cancer Immunotherapy Market Analysis

Netherlands Cancer Immunotherapy Market Executive Analysis

Netherlands's cancer immunotherapy market is expected to witness growth from $293 Mn in 2022 to $526 Mn in 2030 with a CAGR of 7.6% for the forecasted year 2022-30. As part of a $436 Bn overall budget, the Netherlands' budget provides $19 Bn to help increase purchasing power by nearly 4 %. The monthly cost of the basic health insurance package will increase by a maximum of $12, or more than 8%, to $151. The highest monthly healthcare allowance will rise to $170. Only for 2023 will there be a temporary increased healthcare allowance of $454 implemented. In 2023, the expected cost of healthcare will surpass $110 Bn for the first time.

Except for Ireland and Denmark, the Netherlands has relatively more cancer instances than any other nation in Europe, with colon, melanoma, and breast cancer being the most prevalent types of the disease. Oesophageal, bladder, and lung cancer are also far more common in the Netherlands than in the majority of other European nations. In the Netherlands, cancer strikes women more frequently, especially breast and lung cancer, whereas prostate cancer strikes males more frequently than in other European nations.

Immunotherapy is no longer the newest cancer treatment on the block. Oncologists currently use it as a common procedure to treat a wide variety of malignancies. Immunotherapy's function in treatment has changed significantly during the past couple of decades, much to what happened with targeted therapies. ICIs like pembrolizumab were initially only used to treat patients with extremely advanced malignancies that were no longer responding to conventional therapies. Many are currently employed as initial therapies for advanced malignancies, including formerly challenging cancers like kidney and lung. It is not novel to use Immune Checkpoint Inhibitors (ICIs) in neoadjuvant therapy. For some women with early-stage triple-negative breast cancer, the Food and Drug Administration (FDA) has already approved pembrolizumab paired with chemotherapy as a neoadjuvant therapy (followed by surgery and more pembrolizumab). And for early-stage lung cancer, nivolumab (Opdivo) in combination with chemotherapy is authorized as neoadjuvant therapy (followed by surgery). Neoadjuvant therapy is justified in large part by the possibility that smaller tumours may result in procedures that are more successful and less invasive. Additionally, according to some research, immunotherapy administered prior to surgical removal of the tumour results in a more potent immune response against the tumour.

Market Dynamics

Market Growth Drivers

Cancer is becoming more common in the Netherlands, which is projected to increase demand for cancer immunotherapy. The Netherlands Cancer Registry estimates that in 2020, there will be 118,000 new cases of cancer in the nation. The Dutch government and private investors are funding cancer immunotherapy research and development. This investment is anticipated to result in the creation of novel and cutting-edge cancer immunotherapy therapies, further fueling the Netherlands cancer immunotherapy market's expansion. The regulatory framework in the Netherlands is hospitable for the creation and endorsement of cancer immunotherapy medicines. Pharmaceutical companies are anticipated to invest in the Dutch market as a result of the regulatory environment.

Market Restraints

The cost of cancer immunotherapy treatments can be expensive and this may make them less accessible for some patients. This might lower the overall demand in the Netherlands for cancer immunotherapy treatments. The Dutch healthcare system offers universal coverage, although there may be restrictions on cancer immunotherapy reimbursement. This would make it challenging for patients to get these medicines, which might stop the Netherlands cancer immunotherapy market from expanding. Immunotherapy can cause negative effects, much like all other cancer treatments. Even though these side effects are frequently less severe than those related to chemotherapy, individuals and medical professionals may nonetheless be concerned about them. This might restrict the use of cancer immunotherapy in the Netherlands.

Competitive Landscape

Key Players

• Ace Pharmaceuticals (NLD)
• CanAdelaar (NLD)
• Endoca (NLD)
• Bedrocan (NLD)
• Pharmaline (NLD)
• Bayer
• AstraZeneca
• Bristol-Myers Squibb
• F. Hoffmann-La Roche
• Pfizer
• Eli Lily
• Novartis
• Johnson & Johnson
• Merck

Healthcare Policies and Regulatory Landscape

Everyone must have health insurance under the Dutch healthcare system, which is based on the solidarity principle. Although private health insurance providers offer health insurance in the Netherlands, the government establishes the fundamental package of covered services, which includes cancer treatments. A deductible is a predetermined sum that patients are responsible for paying out-of-pocket every year before their insurance coverage kicks in. The Dutch government has produced regulations that specify which therapies are covered and under what circumstances in terms of reimbursement standards for cancer immunotherapy treatments. The recommendations are based on the data that is currently available on the efficacy and safety of the treatments. In the Netherlands, health insurance generally covers cancer immunotherapy therapies; however, reimbursement regulations can change depending on the specific treatment and the patient's condition. The Dutch government also has a procedure for determining if new cancer therapies, such as immunotherapy, are cost-effective. The Zorginstituut Nederland (Dutch Healthcare Institute) examination is the name of this procedure. The evaluation takes into account the treatment's clinical efficacy, price, and effect on the total healthcare budget. The government may opt not to cover the treatment or negotiate the cost with the manufacturer based on the assessment.